Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ensysce Biosciences, Inc.ENSC · Entity 8108 | Director | June 23, 2022 | June 27, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ensysce Biosciences, Inc.
Report date June 23, 2022 · Filed June 27, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2032-06-23 | Direct | 35,000 |
Reported balance
After 2022-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-23 · Grant · Acquired 15,000 · Balance 35,000 F1: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Viridian Therapeutics, Inc.\DE
Report date January 15, 2021 · Filed January 19, 2021
Section 16 reporting ended · disclosed 2021-01-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.03 · Expires 2031-01-17 | Direct | 15,000 |
Reported balance
After 2021-01-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-18 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests in equal monthly installments over the following 6 months, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments over the following 6 months, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2022 Filed Jun 27, 2022 17:41 UTC | Ensysce Biosciences, Inc. ENSC · Entity 8108 | GrantStock Option · Derivative | 15,000 | Not disclosed Strike: $0.43 | Not disclosed |
DisclosureSEC source: 0001493152-22-017877 · ownership.xml · derivative · entry 1 Rauch Lee M. · CIK 0001815345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-23 F1 · security: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. F1 · price: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. F1 · derivative.exercise_date: On June 23, 2022, Ms. Rauch was granted an option (the "Stock Option") to purchase 15,000 shares of common stock of Ensysce Biosciences, Inc. (the "Company"), par value $0.0001 per share, with a per share exercise price of $0.425, under the Amended and Restated 2021 Omnibus Incentive Plan of the Company. The Stock Option vests 1/12th per month over one year. Read SEC document |
| January 18, 2021 Filed Jan 19, 2021 20:04 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002402 · doc4.xml · derivative · entry 1 Rauch Lee M. · CIK 0001815345 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests in equal monthly installments over the following 6 months, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| September 14, 2020 Filed Sep 15, 2020 21:45 UTC | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-20-050617 · doc4.xml · derivative · entry 1 Rauch Lee M. · CIK 0001815345 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2030-09-13 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in 48 equal monthly installments beginning on October 14, 2020, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
| September 13, 2020 Filed Sep 17, 2020 17:31 UTC Amendment | Viridian Therapeutics, Inc.\DE MGEN · Entity 4316 | GrantStock Option (right to buy) · Derivative | 900,000 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001209191-20-050986 · doc4a.xml · derivative · entry 1 Rauch Lee M. · CIK 0001815345 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2020-09-12 F1 · date: This amended Form 4 is being filed to correct the date of grant and related terms. F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2016 Equity Incentive Plan (the "Plan"). The shares vest in 48 equal monthly installments beginning on October 13, 2020, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in and as determined under the Plan. The shares underlying the option are subject to accelerated vesting upon the occurrence of specified events including a change of control of the Issuer and the Reporting Person's termination. The option expires ten years after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.